CAR-T
Drug
Celgene Corporation
Total Payments
$3.6M
Transactions
93
Doctors
21
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $602,975 | 81 | 20 |
| 2018 | $2.9M | 12 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.5M | 14 | 98.3% |
| Consulting Fee | $57,175 | 21 | 1.6% |
| Travel and Lodging | $2,851 | 14 | 0.1% |
| Food and Beverage | $1,925 | 44 | 0.1% |
Payments by Type
Research
$3.5M
14 transactions
General
$61,952
79 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CD1941BBL-BCM-TRIDE-1525 - A Phase 1 Study of CD1941BBL in Combination with BCM for Patients with Advanced Cancer." | Celgene Corporation | $1.1M | 0 |
| FCARH143 rr MMMono-1525 - Phase I trial of FCARH143 in relapsed/refractory multiple myeloma2 | Celgene Corporation | $717,778 | 0 |
| A Phase 1 Study of CD1941BBL in Combination with BCM for Patients with Advanced Cancer." (CD1941BBL-BCM-TRIDE) | Celgene Corporation | $441,301 | 0 |
| FCARH143 rr MMGSI-1525 - Phase I trial of FCARH143 with crenigacestat (GSI) in relapsed/refractory multiple myeloma1 | Celgene Corporation | $249,277 | 0 |
| Unraveling the peptide presentation landscape to inform HLA-restricted immune targeting AML | Celgene Corporation | $225,000 | 0 |
| JCAR014-BCM-1525 - CD19 CAR T Cell Therapy Yield High MRD-Negativity in R/R CLL5 | Celgene Corporation | $144,251 | 0 |
| JCAR020-MUC16IL12-O-1525 - A Phase 1 Study of JCAR020 in Combination with MUC16-IL12 for Patients with Advanced Solid Tumors | Celgene Corporation | $123,809 | 0 |
| JCARH125 Non-spec-1525 - An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma | Celgene Corporation | $108,333 | 0 |
| A Phase 1 Study of JCAR020 in Combination with MUC16-IL12 for Patients with Advanced Solid Tumors (JCAR020-MUC16IL12-O) | Celgene Corporation | $94,804 | 0 |
| 2727 WT-1 TCR NSCLC - Phase I/II Study in WT1-Expressing Non-small Cell Lung Cancer and Mesothelioma, Comparing Cellular Adoptive Immunotherapy With Polyclonal Autologous Central Memory to Na ve CD8+ T Cells That Have Been | Celgene Corporation | $91,487 | 0 |
| JUNO T-CELL ENGINEERING | Celgene Corporation | $75,503 | 0 |
| MCARH171 MM-Mono&Len-1525 - Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma | Celgene Corporation | $62,572 | 0 |
| Transposable Elements and TCR Therapeutics for Lung and Ovarian Adenocarcinoma | Celgene Corporation | $46,356 | 0 |
| A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/?Refractory CD19+ Leukemia (PLAT02) | Celgene Corporation | $6,918 | 0 |
Top Doctors Receiving Payments for CAR-T
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Seattle, WA | $3.5M | 14 |
| , M.D | Internal Medicine | Tampa, FL | $8,006 | 8 |
| , M.D | Hematology & Oncology | Miami, FL | $6,164 | 5 |
| , MD | Medical Oncology | Philadelphia, PA | $5,987 | 8 |
| , MD | Medical Oncology | New York, NY | $5,644 | 5 |
| , M.D | Hematology | Houston, TX | $4,664 | 4 |
| , MD | Hematology & Oncology | Milwaukee, WI | $3,500 | 1 |
| Joel Lopez-Figueroa | Hematology & Oncology | San Juan, PR | $3,361 | 8 |
| , MD | Hematology & Oncology | Long Beach, NY | $3,164 | 4 |
| , MD | Hematology & Oncology | Orlando, FL | $2,695 | 1 |
| , MD, PHD | Internal Medicine | Ann Arbor, MI | $2,424 | 4 |
| , MD | Hematology & Oncology | Fernandina Beach, FL | $2,424 | 4 |
| , M.D | Medical Oncology | Tacoma, WA | $2,424 | 4 |
| , M.D | Specialist | Atlanta, GA | $2,424 | 4 |
| , M.D | Hematology | Fort Myers, FL | $2,304 | 3 |
| , MD | Medical Oncology | Bronx, NY | $2,000 | 1 |
| , M.D | Medical Oncology | Olean, NY | $1,704 | 4 |
| , M.D | Hematology & Oncology | Clermont, FL | $1,704 | 4 |
| , D.O | Internal Medicine | Omaha, NE | $1,276 | 4 |
| , MD, PHD | Medical Oncology | New York, NY | $29.33 | 1 |
| , MD | Pediatric Hematology-Oncology | Seattle, WA | $25.95 | 1 |
| , MD | Medical Oncology | Saint Louis, MO | $23.65 | 1 |
Ad
Manufacturing Companies
- Celgene Corporation $3.6M
Product Information
- Type Drug
- Total Payments $3.6M
- Total Doctors 21
- Transactions 93
About CAR-T
CAR-T is a drug associated with $3.6M in payments to 21 healthcare providers, recorded across 93 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2018 to 2019. In 2019, $602,975 was paid across 81 transactions to 20 doctors.
The most common payment nature for CAR-T is "Unspecified" ($3.5M, 98.3% of total).
CAR-T is associated with 14 research studies, including "CD1941BBL-BCM-TRIDE-1525 - A Phase 1 Study of CD1941BBL in Combination with BCM for Patients with Advanced Cancer."" ($1.1M).